Takeda’s phase 2b study of Mezagitamab shows potential to transform treatment of primary immune… EP News Bureau Jun 24, 2024 Takeda Plans to Initiate Global Phase 3 Trial of Mezagitamab in ITP in the Second Half of FY2024
